TipRanks
Alnylam Pharmaceuticals (DE:DUL)
XETRA:DUL
Germany Market
DUL
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (DUL) Stock News & Sentiment

4 Followers
Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names
Premium
Market News
Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names
8d ago
ALNY
BTSG
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
Premium
Ratings
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
9d ago
ALNY
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
Premium
Ratings
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
14d ago
ALNY
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
Premium
Ratings
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
24d ago
ALNY
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
Premium
Ratings
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
26d ago
ALNY
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
Premium
Ratings
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
26d ago
ALNY
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
Premium
Ratings
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
26d ago
ALNY
More DE:DUL News >

DUL News on the Web

Alnylam Stock Stumbles as Hot Streak Cools
TipRanks News
Neutral
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript
GuruFocus News
Neutral
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)
TipRanks News
Bullish
Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
TipRanks News
Neutral
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
Insider Monkey
Bearish
Deep Track Capital, LP Acquires Jatt III Acquisition Corp (JTTT) Shares on IPO Day
GuruFocus News
Neutral

News Score - Last 7 Days

Neutral
DE:DUL
Sector Average
Media Buzz
This Week2 articles
Weekly Average10 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:DUL’s Media Buzz Sentiment?
2 articles about DE:DUL were published this week. In an average week, 10 articles are published.
    What is DE:DUL’s weekly average amount of articles?
    In an average week, 10 articles about DE:DUL are published.
      What is DE:DUL’s News Sentiment?
      100% of articles about DE:DUL were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        ENTXEntera Bio
        VEEVVeeva Systems
        HELPHelus Pharma
        LGNDLigand Pharma
        ANABAnaptysBio
        Showing the stocks with the most bullish news sentiment over the past week